Celldex Therapeutics (CLDX) : During the past 4 weeks, traders have been relatively bearish on Celldex Therapeutics (CLDX), hence the stock is down -6.08% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -4.34% relative to the S&P 500. The 4-week change in the price of the stock is -5.11% and the stock has fallen -4.29% in the past 1 week.
The stock has recorded a 20-day Moving Average of 3.7% and the 50-Day Moving Average is 1.59%. Celldex Therapeutics (NASDAQ:CLDX): stock turned positive on Friday. Though the stock opened at $4.35, the bulls momentum made the stock top out at $4.5 level for the day. The stock recorded a low of $4.32 and closed the trading day at $4.46, in the green by 2.29%. The total traded volume for the day was 1,303,416. The stock had closed at $4.36 in the previous days trading.
The company Insiders own 4.2% of Celldex Therapeutics shares according to the proxy statements. Institutional Investors own 82.03% of Celldex Therapeutics shares. Also, Jefferies maintains its rating on Celldex Therapeutics (NASDAQ:CLDX). The global brokerage major raises the current price target from $4 per share to $5 per share. Analysts at the Jefferies have a current rating of Hold on the shares. The rating by the firm was issued on August 9, 2016.
Celldex Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases. Its lead drug candidates include rindopepimut also referred to as Rintega and CDX-110 and glembatumumab vedotin also referred to as CDX-011. Its early-stage drug candidates in clinical development, includes varlilumab also referred to as CDX-1127, a fully human therapeutic monoclonal antibody for cancer indications, CDX-1401, a targeted immunotherapeutic for cancer indications and CDX-301, an immune cell mobilizing agent and dendritic cell growth factor. CDX-014 is a preclinical product under development for the treatment of cancer.